Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002280 · ClinicalTrials.gov registry record · NA
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
A NA study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- NA
- Development phase
NCT00002280: Completed NA study, sponsored by Bristol-Myers Squibb.
NCT00002280 is a NA study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002280, a NA study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
Interventions
- DRUG Didanosine
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 1994-11 |
| Phase | NA |
What the finished NCT00002280 record still lists
NCT00002280 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Didanosine is the first listed.
NCT00002280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002280 about?
NCT00002280 is a clinical study titled "A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine". The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
What is the current status of trial NCT00002280?
This trial is currently completed. It is a NA study. Estimated completion is 1994-11.
What interventions are being tested in trial NCT00002280?
The interventions under investigation include: Didanosine (DRUG).
Who is sponsoring clinical trial NCT00002280?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.